A screen for MeCP2-TBL1 interaction inhibitors using a luminescence-based assay

A screen for MeCP2-TBL1 interaction inhibitors using a luminescence-based assay

Abstract Understanding the molecular pathology of neurodevelopmental disorders should aid the development of therapies for these conditions. In MeCP2 duplication syndrome (MDS)—a severe autism spectrum disorder—neuronal dysfunction is caused by increased levels of MeCP2. MeCP2 is a nuclear protein t...

Full description

Bibliographic Details
Main Authors: Beatrice Alexander-Howden, Li Zhang, Almer M. van der Sloot, Sylvain Tollis, Daniel J. St-Cyr, Frank Sicheri, Adrian P. Bird, Mike Tyers, Matthew J. Lyst
Format: Article
Language:English
Published: Nature Portfolio 2023-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-29915-z

Internet

https://doi.org/10.1038/s41598-023-29915-z

Similar Items